Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks MaxCyte ( (MXCT)) has provided an ...

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE)-- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...

An announcement from MaxCyte ( (MXCT)) is now available. On May 12, 2026, MaxCyte reported first-quarter 2026 revenue of $9.7 million, down 7% year on year, with core business revenue falling 25% to ...

VectorBuilder made an agreement with MaxCyte, a biotechnology and electroporation company. The partnership will focus on ...

Minot Light Capital Partners, an investment management company, released its "Capital Appreciation Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% ...

Short interest in MaxCyte Inc (NASDAQ:MXCT) increased during the last reporting period, rising from 2.98M to 3.29M. This put 3.13% of the company's publicly available shares short. Short interest in ...

Maryland-based MaxCyte focuses on cell-engineering platform technology to serve the biotech industry. In its preliminary report, the cell engineering company lowered its full-year guidance and relayed ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement. Full year 2025 revenue of $33.0 million, at the top of the range of ...

ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (MXCT),, a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of ...

MaxCyte Inc MXCT shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decrease of 25 -27%, due to continued reduced customer activity in the sector.

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the ...